A novel chemotactic factor derived from the extracellular matrix protein decorin recruits mesenchymal stromal cells in vitro and in vivo

PLoS One. 2020 Jul 13;15(7):e0235784. doi: 10.1371/journal.pone.0235784. eCollection 2020.

Abstract

Soft tissue is composed of cells surrounded by an extracellular matrix that is made up of a diverse array of intricately organized proteins. These distinct components work in concert to maintain homeostasis and respond to tissue damage. During tissue repair, extracellular matrix proteins and their degradation products are known to influence physiological processes such as angiogenesis and inflammation. In this study we developed a discovery platform using a decellularized extracellular matrix biomaterial to identify new chemotrophic factors derived from the extracellular matrix. An in vitro culture of RAW.264 macrophage cells with the biomaterial ovine forestomach matrix led to the identification of a novel ~12 kDa chemotactic factor, termed 'MayDay', derived from the N-terminal 31-188 sequence of decorin. The recombinant MayDay protein was shown to be a chemotactic agent for mesenchymal stromal cells in vitro and in vivo. We hypothesize that the macrophage-induced cleavage of decorin, via MMP-12, leads to the release of the chemotactic molecule MayDay, that in turn recruits cells to the site of damaged tissue.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Cells, Cultured
  • Chemotactic Factors / chemistry
  • Chemotactic Factors / pharmacology*
  • Chemotaxis / drug effects
  • Decorin / chemistry
  • Decorin / pharmacology*
  • Mesenchymal Stem Cells / cytology
  • Mesenchymal Stem Cells / drug effects*
  • Mice
  • Peptide Fragments / chemistry
  • Peptide Fragments / pharmacology*
  • RAW 264.7 Cells
  • Recombinant Proteins / chemistry
  • Recombinant Proteins / pharmacology
  • Sheep

Substances

  • Chemotactic Factors
  • Decorin
  • Peptide Fragments
  • Recombinant Proteins

Grants and funding

Funding for this project was received by Aroa Biosurgery Limited (New Zealand) from Callaghan Innovation Limited (Wellington, New Zealand) (www.callaghaninnovation.govt.nz website) via a Growth Grant (MSMA1402). This funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Aroa Biosurgery Limited provided materials and funding to this project as well as support in the form of salaries for authors (BCHM,SGD, RWFV), but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section.